{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T11:33:56Z","timestamp":1793360036585,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.ajo.2023.03.027","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T22:38:13Z","timestamp":1680734293000},"page":"94-100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease"],"prefix":"10.1016","volume":"252","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7320-5574","authenticated-orcid":false,"given":"Petros","family":"Perros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9977-5970","authenticated-orcid":false,"given":"Milo\u0161","family":"\u017darkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9047-1556","authenticated-orcid":false,"given":"Salman","family":"Razvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Kolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Jane","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0001","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 Update on clinical management of Graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"6","key":"10.1016\/j.ajo.2023.03.027_bib0002","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-22-0189","article-title":"Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association","volume":"11","author":"Burch","year":"2022","journal-title":"Eur Thyroid J"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0003","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","article-title":"Advances in treatment of active, moderate-to-severe Graves' ophthalmopathy","volume":"5","author":"Wiersinga","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2023.03.027_bib0004","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1210\/clinem\/dgac328","article-title":"Understanding pathogenesis intersects with effective treatment for thyroid eye disease","volume":"107","author":"Smith","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"4S Suppl 1","key":"10.1016\/j.ajo.2023.03.027_bib0005","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1097\/IOP.0000000000001150","article-title":"Grading severity and activity in thyroid eye disease","volume":"34","author":"Dolman","year":"2018","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"3","key":"10.1016\/j.ajo.2023.03.027_bib0006","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1530\/EJE-15-1164","article-title":"Endocrine dilemma: management of Graves' orbitopathy","volume":"175","author":"Campi","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ajo.2023.03.027_bib0007","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bjo.73.8.639","article-title":"Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach","volume":"73","author":"Mourits","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ajo.2023.03.027_bib0008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.ajo.2023.03.027_bib0009","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ajo.2023.03.027_bib0010","unstructured":"LG2 Lighting for healthcare premises. 2019.. Accessed March 3, 2023. https:\/\/www.cibse.org\/knowledge-research\/knowledge-portal\/lighting-guide-02-lighting-for-healthcare-premises-2019"},{"issue":"3","key":"10.1016\/j.ajo.2023.03.027_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1365-2265.2001.01349.x","article-title":"Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment","volume":"55","author":"Dickinson","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ajo.2023.03.027_bib0012","first-page":"411","article-title":"Reliability in content analysis: some common misconceptions and recommendations","volume":"30","author":"Krippendorff","year":"2004","journal-title":"Hum Com Res"},{"issue":"1","key":"10.1016\/j.ajo.2023.03.027_bib0013","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13023-017-0625-1","article-title":"Graves' orbitopathy as a rare disease in Europe: a European Group on Graves' Orbitopathy (EUGOGO) position statement","volume":"12","author":"Perros","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.ajo.2023.03.027_bib0014","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ajo.2023.03.027_bib0015","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1210\/clinem\/dgac252","article-title":"Future projections in thyroid eye disease","volume":"107","author":"Barbesino","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ajo.2023.03.027_bib0016","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF03347327","article-title":"The use of colour slides in the assessment of changes in soft-tissue involvement in Graves' ophthalmopathy","volume":"21","author":"Gerding","year":"1998","journal-title":"J Endocrinol Invest"},{"issue":"18","key":"10.1016\/j.ajo.2023.03.027_bib0017","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ajo.2023.03.027_bib0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ajo.2023.03.027_bib0019","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1210\/jc.2012-2389","article-title":"Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy","volume":"97","author":"Bartalena","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0020","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","article-title":"Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study","volume":"100","author":"Salvi","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ajo.2023.03.027_bib0021","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy","volume":"89","author":"Prummel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ajo.2023.03.027_bib0022","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/105072502753600232","article-title":"Radiotherapy for Graves' ophthalmopathy: results at one year","volume":"12","author":"Gorman","year":"2002","journal-title":"Thyroid"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0023","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","article-title":"Randomized controlled trial of rituximab in patients with Graves' orbitopathy","volume":"100","author":"Stan","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ajo.2023.03.027_bib0024","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves' orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0025","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/cen.13170","article-title":"Efficacy and safety of mycophenolate mofetil in patients with active moderate-to-severe Graves' orbitopathy","volume":"86","author":"Ye","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1016\/j.ajo.2023.03.027_bib0026","article-title":"Ensemble neural network model for detecting thyroid eye disease using external photographs","author":"Karlin","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0027","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2265.2005.02186.x","article-title":"Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy","volume":"62","author":"Terwee","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"10.1016\/j.ajo.2023.03.027_bib0028","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","article-title":"Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy","volume":"52","author":"Gerding","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"10.1016\/j.ajo.2023.03.027_bib0029","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1507\/endocrj.EJ14-0246","article-title":"Circulating levels of miR-146a and IL-17 are significantly correlated with the clinical activity of Graves' ophthalmopathy","volume":"61","author":"Wei","year":"2014","journal-title":"Endocr J"},{"issue":"10","key":"10.1016\/j.ajo.2023.03.027_bib0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1007\/s00417-012-2092-7","article-title":"Increased serum interleukin-17 in Graves' ophthalmopathy","volume":"250","author":"Kim","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"5","key":"10.1016\/j.ajo.2023.03.027_bib0031","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/197140091302600509","article-title":"Disease activity in Graves' ophthalmopathy: diagnosis with orbital MR imaging and correlation with clinical score","volume":"26","author":"Tortora","year":"2013","journal-title":"Neuroradiol J"},{"issue":"10","key":"10.1016\/j.ajo.2023.03.027_bib0032","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1055\/s-0033-1349891","article-title":"A pilot study evaluating 99mTc-anti-TNF-alpha scintigraphy in Graves' ophthalmopathy patients with different clinical activity score","volume":"45","author":"Rebelo Pinto Edos","year":"2013","journal-title":"Horm Metab Res"},{"issue":"2","key":"10.1016\/j.ajo.2023.03.027_bib0033","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41433-018-0304-z","article-title":"T2-relaxation mapping and fat fraction assessment to objectively quantify clinical activity in thyroid eye disease: an initial feasibility study","volume":"33","author":"Das","year":"2019","journal-title":"Eye (Lond)"},{"issue":"12","key":"10.1016\/j.ajo.2023.03.027_bib0034","doi-asserted-by":"crossref","first-page":"4600","DOI":"10.1210\/jc.2014-1957","article-title":"Novel thermal imaging analysis technique for detecting inflammation in thyroid eye disease","volume":"99","author":"Di Maria","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ajo.2023.03.027_bib0035","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejrad.2005.03.027","article-title":"Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease","volume":"56","author":"Mayer","year":"2005","journal-title":"Eur J Radiol"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300140X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293942300140X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T13:53:05Z","timestamp":1757598785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293942300140X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":35,"alternative-id":["S000293942300140X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2023.03.027","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inter-observer Variability of Clinical Activity Score: Assessments in Patients With Thyroid Eye Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2023.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}